Search Results - "Borra, Lennaert C"

  • Showing 1 - 6 results of 6
Refine Results
  1. 1

    A high intrapatient variability in tacrolimus exposure is associated with poor long-term outcome of kidney transplantation by Shuker, Nauras, Shuker, Lamis, van Rosmalen, Joost, Roodnat, Joke I, Borra, Lennaert C P, Weimar, Willem, Hesselink, Dennis A, van Gelder, Teun

    Published in Transplant international (01-11-2016)
    “…Tacrolimus is a critical dose drug with a considerable intrapatient variability (IPV) in its pharmacokinetics. We investigated whether a high IPV in tacrolimus…”
    Get more information
    Journal Article
  2. 2

    High within-patient variability in the clearance of tacrolimus is a risk factor for poor long-term outcome after kidney transplantation by Borra, Lennaert C.P., Roodnat, Joke I., Kal, Judith A., Mathot, Ron A.A., Weimar, Willem, van Gelder, Teun

    Published in Nephrology, dialysis, transplantation (01-08-2010)
    “…Background. We hypothesized that a high within-patient variability in clearance of tacrolimus and mycophenolate mofetil (MMF) would put patients at risk for…”
    Get full text
    Journal Article
  3. 3

    Successful Systemic and Topical Treatment of Mycobacterium abscessus Otomastoiditis by van Wijk, Floor, Waterval, Jérôme, van Aerde, Koen, Henriet, Stefanie S V, Meijer, F J Anton, Borra, Lennaert C, Aarnoutse, Rob E, van Ingen, Jakko

    Published in Antimicrobial agents and chemotherapy (20-12-2019)
    “…is an extensively drug-resistant opportunistic pathogen that can cause chronic otomastoiditis. There are no evidence-based treatment regimens for this severe…”
    Get full text
    Journal Article
  4. 4
  5. 5
  6. 6

    Adequacy of a hospital-wide standard dose of 7mg/kg bodyweight gentamicin sufficient to achieve an adequate prophylactic maximum serum concentration (Cmax) in burn patients undergoing surgical burn wound treatment by Borra, Lennaert C.P., Bosch, Tessa M., van Baar, Margriet E., Dokter, Jan, Oen, Irma M., Ruijgrok, Elisabeth J.

    Published in Burns (01-12-2016)
    “…•Pharmacokinetics can be significantly altered in the burn patient.•We investigated whether this is relevant for prophylactic dosing of gentamicin.•90% (36/40)…”
    Get full text
    Journal Article